INMED PHARMACEUTICALS INC. Accounts Payable and Other Accrued Liabilities
INMED PHARMACEUTICALS INC. (INM) had Accounts Payable and Other Accrued Liabilities of CAD 1.97 million as of 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Balance Sheet › Liabilities
us-gaap:AccountsPayableAndOtherAccruedLiabilities · last filed 2023-05-15
- 2023-03-31: Accounts Payable and Other Accrued Liabilities 1.97M CAD.
- 2022-12-31: Accounts Payable and Other Accrued Liabilities 1.55M CAD.
- 2022-09-30: Accounts Payable and Other Accrued Liabilities 1.71M CAD.
- 2022-06-30: Accounts Payable and Other Accrued Liabilities 2.05M CAD.
CAD
| Period end | Accounts Payable and Other Accrued Liabilities |
|---|---|
| 2023-03-31 | 1.97M CAD 10-Q · filed 2023-05-15 |
| 2022-12-31 | 1.55M CAD 10-Q · filed 2023-02-17 |
| 2022-09-30 | 1.71M CAD 10-Q · filed 2022-11-14 |
| 2022-06-30 | 2.05M CAD 10-K · filed 2022-09-23 |
| 2022-03-31 | 1.57M CAD 10-Q · filed 2022-05-13 |
| 2021-12-31 | 2.64M CAD 10-Q · filed 2022-02-14 |
| 2021-09-30 | 2.44M CAD 10-Q · filed 2021-11-10 |
| 2021-06-30 | 1.53M CAD 10-K · filed 2021-09-24 |
| 2021-03-31 | 2.44M CAD 10-Q · filed 2021-05-13 |
| 2020-12-31 | 7.67M CAD 10-Q · filed 2021-02-11 |
| 2020-09-30 | 333.87K CAD 10-Q · filed 2020-12-17 |
USD
| Period end | Accounts Payable and Other Accrued Liabilities |
|---|---|
| 2023-03-31 | $1.45M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $1.15M 10-Q · filed 2023-02-17 |
| 2022-09-30 | $1.25M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $1.59M 10-K · filed 2022-09-23 |
| 2022-03-31 | $1.26M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $2.08M 10-Q · filed 2022-02-14 |
| 2021-09-30 | $1.92M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $1.24M 10-K · filed 2021-09-24 |
| 2021-03-31 | $1.94M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $6.02M 10-Q · filed 2021-02-11 |
| 2020-09-30 | $250.29K 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |